O. Eizenberg

发表

Reduced levels of α1 (I) collagen mRNA in cells immortalized by mutant p53 or transformed by ras

M. Oren, O. Eizenberg, 1991 .

Development of Novel Promiscuous Anti-Chemokine Peptibodies for Treating Autoimmunity and Inflammation

E. Galun, A. Peled, O. Eizenberg, 2017, Front. Immunol..

Single Dose of the CXCR4 Antagonist BL-8040 Induces Rapid Mobilization for the Collection of Human CD34+ Cells in Healthy Volunteers

A. Nagler, E. Galun, A. Peled, 2017, Clinical Cancer Research.

The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression

Ido D. Weiss, A. Nagler, E. Galun, 2017, Leukemia.

Cancer Therapy : Clinical The High-Af fi nity CXCR 4 Antagonist BKT 140 Is Safe and Induces a Robust Mobilization of Human CD 34 þ Cells in Patients with Multiple Myeloma

A. Nagler, E. Galun, A. Peled, 2014 .

The high-affinity CXCR 4 antagonist BKT 140 is safe and induces a robust mobilization of human CD 34 + cells in patients with multiple myeloma

A. Nagler, E. Galun, A. Peled, 2013 .

The High-Affinity CXCR4 Antagonist BKT140 Is Safe and Induces a Robust Mobilization of Human CD34+ Cells in Patients with Multiple Myeloma

A. Nagler, E. Galun, A. Peled, 2013, Clinical Cancer Research.

Sequential administration of the high affinity CXCR4 antagonist BKT140 promotes megakaryopoiesis and platelet production

Ido D. Weiss, A. Nagler, A. Peled, 2013, British journal of haematology.

The CXCR4 antagonist 4F-benzoyl-TN14003 stimulates the recovery of the bone marrow after transplantation

Ido D. Weiss, A. Nagler, E. Galun, 2009, Leukemia.

CXCR4 antagonist 4F-benzoyl-TN14003 inhibits leukemia and multiple myeloma tumor growth.

Ido D. Weiss, A. Nagler, E. Galun, 2011, Experimental hematology.

Cancer Therapy : Preclinical Targeting the CD 20 and CXCR 4 Pathways in Non-Hodgkin Lymphoma with Rituximab and High-Af fi nity CXCR 4 Antagonist BKT 140

A. Nagler, E. Galun, A. Peled, 2013 .

Interleukin‐2 Transcripts in Human and Rodent Brains: Possible Expression by Astrocytes

M. Schwartz, O. Eizenberg, A. Faber‐Elman, 1995, Journal of neurochemistry.

Oligodendrocytes and Axonal Regrowth

M. Schwartz, O. Eizenberg, S. Eitan, 1997 .

Direct involvement of p53 in programmed cell death of oligodendrocytes.

V. Rotter, M. Schwartz, M. Oren, 1995, The EMBO journal.

Linear dimeric interleukin-2 obtained by the use of a defective herpes simplex viral vector: conformation-activity relationship.

D. Pfaff, M. Kaplitt, O. Eizenberg, 1994, Brain research. Molecular brain research.

Combination of Imatinib with CXCR4 Antagonist BKT140 Overcomes the Protective Effect of Stroma and Targets CML In Vitro and In Vivo

A. Nagler, E. Galun, A. Peled, 2012, Molecular Cancer Therapeutics.

Combination of Imatinib with CXCR 4 antagonist BKT 140 overcomes the protective effect of stroma and targets CML in vitro and in vivo

A. Nagler, E. Galun, A. Peled, 2013 .

The CXCR4 Antagonist BL-8040 Induces a Robust Mobilization of CD34+CD38−CD45RA−CD90+ CD49f+ HSCs with Long-Term and Secondary Myeloid and Lymphoid Repopulating Activity

A. Nagler, E. Galun, A. Peled, 2017 .

CXCR4 Promotes Neuroblastoma Growth and Therapeutic Resistance through miR-15a/16-1-Mediated ERK and BCL2/Cyclin D1 Pathways.

Ido D. Weiss, E. Galun, A. Peled, 2018, Cancer research.

Sequence homology within the morbilliviruses

W. Bellini, O. Eizenberg, S. Rozenblatt, 1985, Journal of virology.

A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice.

Y. Cohen, Y. Assaf, O. Eizenberg, 2001, The Journal of pharmacology and experimental therapeutics.

In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non-small cell lung cancer.

Ido D. Weiss, A. Peled, O. Eizenberg, 2012, The Journal of thoracic and cardiovascular surgery.

p53 plays a regulatory role in differentiation and apoptosis of central nervous system-associated cells

V. Rotter, M. Schwartz, M. Oren, 1996, Molecular and cellular biology.

Targeting the CD20 and CXCR4 Pathways in Non-Hodgkin Lymphoma with Rituximab and High-Affinity CXCR4 Antagonist BKT140

Arnon Nagler, Amnon Peled, A. Nagler, 2013, Clinical Cancer Research.

Effect of BL-8040, high-affinity CXCR4 antagonist, on T-cell infiltration, tumor growth, and synergy with immunomodulatory agents.

A. Peled, O. Eizenberg, Y. Pereg, 2017 .

Promiscuous Chemokine Antagonist (BKT130) Suppresses Laser-Induced Choroidal Neovascularization by Inhibition of Monocyte Recruitment

I. Chowers, A. Peled, O. Eizenberg, 2019, Journal of immunology research.

Expression of GTP-dependent and GTP-independent Tissue-type Transglutaminase in Cytokine-treated Rat Brain Astrocytes*

O. Eizenberg, Y. Paas, A. Monsonego, 1997, The Journal of Biological Chemistry.

BKT140 Is a Novel CXCR4 Antagonist with Stem Cell Mobilization and Antimyeloma Effects: An Open-Label First Human Trial In Patients with Multiple Myeloma Undergoing Stem Cell Mobilization for Autologous Transplantation

A. Nagler, E. Galun, A. Peled, 2010 .

In vitro and in vivo therapeutic efficacy of CXCR 4 antagonist BKT 140 against human non – small cell lung cancer

Ido D. Weiss, A. Peled, O. Eizenberg, 2012 .

Cloning and characterization of DNA complementary to the canine distemper virus mRNA encoding matrix, phosphoprotein, and nucleocapsid protein

W. Bellini, O. Eizenberg, G. Englund, 1985, Journal of virology.

Sequential administration of the high affinity CXCR4 antagonist BKT140 promotes megakaryopoiesis and platelet production

Ido D. Weiss, A. Nagler, A. Peled, 2013, British journal of haematology.

CXCR4 Promotes Neuroblastoma Growth and Therapeutic Resistance through miR-15a/16-1-Mediated ERK and BCL2/Cyclin D1 Pathways.

Ido D. Weiss, E. Galun, A. Peled, 2018, Cancer research.

The CXCR4 Antagonist BL-8040 Efficiently Induces Apoptosis and Inhibits The Survival Of AML Cells

Ido D. Weiss, A. Nagler, A. Peled, 2013 .